Payment overview · 2025
General Payments
$458.34
23 reported records · 14 companies
Healthcare provider profile · identity verified
Stephen Dennis Clark, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CROSSVILLE, TN · NPI 1275727927
Verified facts
What the public records show
CMS Open Payments records show Stephen Dennis Clark, M.D. received $458.34 in general payments during 2025 across 23 reported records.
Antares Pharma, Inc. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $78.62 | 17.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.35 | 12.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.75 | 12.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $46.14 | 10.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.28 | 9.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.75 | 6.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.37 | 5.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.73 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.64 | 4.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.56 | 4.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.81 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.45 | 3.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.95 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.94 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $458.34 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $78.62 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $57.35 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.28 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.28 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.45 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 516 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 393 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 106 |
| Lisinopril | Lisinopril | 344 | 98 |
| Losartan Potassium | Losartan Potassium | 290 | 82 |
| Omeprazole | Omeprazole | 287 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 64 |
| Gabapentin | Gabapentin | 193 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 55 |
| Furosemide | Furosemide | 178 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 43 |
| Eliquis | Apixaban | 136 | 35 |
| Simvastatin | Simvastatin | 135 | 40 |
| Prednisone | Prednisone | 127 | 84 |
| Potassium Chloride | Potassium Chloride | 125 | 44 |
| Sertraline Hcl | Sertraline Hcl | 123 | 32 |
| Trazodone Hcl | Trazodone Hcl | 116 | 39 |
| Ozempic | Semaglutide | 114 | 19 |
| Metformin Hcl Er | Metformin Hcl | 110 | 33 |
| Atenolol | Atenolol | 107 | 27 |
| Jardiance | Empagliflozin | 106 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 30 |
| Celecoxib | Celecoxib | 103 | 38 |
| Carvedilol | Carvedilol | 102 | 28 |
| Metformin Hcl | Metformin Hcl | 100 | 29 |
| Montelukast Sodium | Montelukast Sodium | 93 | 31 |
| Famotidine | Famotidine | 92 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 28 |
| Tramadol Hcl | Tramadol Hcl | 90 | 19 |
| Bupropion Xl | Bupropion Hcl | 76 | 23 |
| Repatha Sureclick | Evolocumab | 74 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 24 |
| Farxiga | Dapagliflozin Propanediol | 72 | 17 |
| Pregabalin | Pregabalin | 71 | 15 |
| Finasteride | Finasteride | 70 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 31 |
| Meloxicam | Meloxicam | 68 | 23 |
| Clonazepam | Clonazepam | 67 | 14 |
| Ezetimibe | Ezetimibe | 67 | 21 |
| Valsartan | Valsartan | 63 | 18 |
| Fenofibrate | Fenofibrate | 61 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 19 |
| Alendronate Sodium | Alendronate Sodium | 57 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 17 |
| Azithromycin | Azithromycin | 56 | 53 |
| Buspirone Hcl | Buspirone Hcl | 54 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 14 |
| Glimepiride | Glimepiride | 51 | 16 |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 19 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Rybelsus | Semaglutide | 41 | suppressed |
| Cefdinir | Cefdinir | 39 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | 11 |
| Allopurinol | Allopurinol | 37 | 14 |
| Baclofen | Baclofen | 36 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 33 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Nystatin | Nystatin | 30 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 17 |
| Donepezil Hcl | Donepezil Hcl | 24 | 11 |
| Fluconazole | Fluconazole | 24 | 19 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 13 |
| Benzonatate | Benzonatate | 19 | 15 |
| Linzess | Linaclotide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Temazepam | Temazepam | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $458.34 · 23 records | Antares Pharma, Inc. | AIRSUPRA, CAPLYTA, FREESTYLE LIBRE 3, Kerendia, LEQVIO, MINIMED 780G, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, SPRAVATO, VOQUEZNA, Wegovy, XYOSTED, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error